World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
72
Citations
23725
World Ranking
19783
National Ranking
9847

James W. Mier publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where James W. Mier sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 241 publications — 7th percentile

7% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

James W. Mier D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where James W. Mier sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 72 D-Index — 2nd percentile

2% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

James W. Mier is affiliated with Beth Israel Deaconess Medical Center in the United States. Their research primarily focuses on medicine, with a significant emphasis on oncology, molecular biology, obstetrics and gynecology, cancer research, and reproductive medicine.

Their scientific work covers various topics related to cancer treatment and molecular biology, including:

  • Endometrial and cervical cancer treatments
  • Cancer immunotherapy and biomarkers
  • Cancer-related molecular pathways
  • Ovarian cancer diagnosis and treatment
  • Angiogenesis and VEGF in cancer
  • Prostate cancer treatment and research
  • CAR-T cell therapy research

James W. Mier has contributed to several publications, primarily in the following venues:

  • Journal of Clinical Oncology
  • Molecular Cancer

Selected recent papers by Mier include:

  • Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer, 2020, Journal of Clinical Oncology
  • Lenvatinib (LEN) plus pembrolizumab (PEMBRO) for early-line treatment of advanced/recurrent endometrial cancer (EC), 2020, Journal of Clinical Oncology
  • Association of an RNA signature (RS) with emergence of ICOS hi CD4 T cells and efficacy outcomes for the ICOS agonist vopratelimab (vopra) and nivolumab (nivo) in patients (pts) on the ICONIC trial, 2020, Journal of Clinical Oncology
  • Retraction Note to: Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells, 2021, Molecular Cancer
  • Retraction Note to: Differential modulatory effects of GSK-3b and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma, 2021, Molecular Cancer

Their frequent collaborators include:

  • Vicky Makker
  • Matthew H. Taylor
  • Carol Aghajanian
  • Ana Oaknin
  • Allen Lee Cohn

Best Publications

  • Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55

    Herbert Tilg;Elizabeth Trehu;Michael B. Atkins;Charles A. Dinarello

  • Arginase-Producing Myeloid Suppressor Cells in Renal Cell Carcinoma Patients: A Mechanism of Tumor Evasion

    Arnold H. Zea;Paulo C. Rodriguez;Michael B. Atkins;Claudia Hernandez

  • Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

    David F. McDermott;Meredith M. Regan;Joseph I. Clark;Lawrence E. Flaherty

  • IL-6 and APPs: anti-inflammatory and immunosuppressive mediators.

    Herbert Tilg;Charles A. Dinarello;James W. Mier

  • Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis

    Arthur Kaser;Gerald Brandacher;Wolfgang Steurer;Susanne Kaser;Susanne Kaser

  • Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.

    Michael B. Atkins;Michael J. Robertson;Michael Gordon;Michael T. Lotze

  • Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth

    George D. Kamphaus;Pablo C. Colorado;David J. Panka;Helmut Hopfer

  • Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

    Jeffrey J. Wallin;Johanna C. Bendell;Roel Funke;Mario Sznol

  • Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer

    Michael Atkins;Meredith Regan;David McDermott;James Mier

  • Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses.

    David Avigan;Baldev Vasir;Jianlin Gong;Virginia Borges

  • Multiple biological activities of human recombinant interleukin 1.

    C A Dinarello;J G Cannon;J W Mier;H A Bernheim

  • Metastatic Renal Cancer Treated with Interleukin-2 and Lymphokine-Activated Killer Cells: A Phase II Clinical Trial

    Fisher Ri;Coltman Ca;Doroshow Jh;Rayner Aa

  • Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor

    Joseph E. Gootenberg;Francis W. Ruscetti;James W. Mier;Adi Gazdar

  • Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.

    Vicky Makker;Drew Rasco;Nicholas J Vogelzang;Marcia S Brose

  • Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells.

    Michael B. Atkins;James W. Mier;David R. Parkinson;Jody A. Gould

  • Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

    Vicky Makker;Matthew H. Taylor;Carol Aghajanian;Ana Oaknin

  • Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.

    Jared A. Gollob;James W. Mier;Korina Veenstra;David F. McDermott

  • Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells.

    David J. Panka;Toshiaki Mano;Toshimitsu Suhara;Kenneth Walsh

  • T-cell lines established from human T-lymphocytic neoplasias by direct response to T-cell growth factor

    Bernard J. Poiesz;Francis W. Ruscetti;James W. Mier;Andrea M. Woods

  • Purification and some characteristics of human T-cell growth factor from phytohemagglutinin-stimulated lymphocyte-conditioned media

    James W. Mier;Robert C. Gallo

Frequent Co-Authors

Michael B. Atkins
Michael B. Atkins Georgetown University
Sabina Signoretti
Sabina Signoretti Brigham and Women's Hospital
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
Charles A. Dinarello
Charles A. Dinarello University of Colorado Anschutz Medical Campus
Jeffrey A. Sosman
Jeffrey A. Sosman Northwestern University
Kim Margolin
Kim Margolin City Of Hope National Medical Center
Ryan J. Sullivan
Ryan J. Sullivan Harvard University
Richard I. Fisher
Richard I. Fisher Fox Chase Cancer Center
David C. Alsop
David C. Alsop Beth Israel Deaconess Medical Center
Geoffrey I. Shapiro
Geoffrey I. Shapiro Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medical studies in the USA opens up a range of allied health careers beyond the traditional MD route. Many students are now choosing flexible online pathways to accelerate or specialize their medical education. For example, easiest online dnp programs appeal to nurses who want to advance into leadership or specialist roles without leaving their current jobs.

If you’re looking for a quicker entry into healthcare, exploring fast track medical programs such as online LPN courses can help you join the workforce sooner. For those interested in mental health, the fastest psych np program options allow registered nurses to specialize rapidly and start making a difference in behavioral health care.

Healthcare administration is another growing field. The best online mha programs offer affordable, flexible education for those who want to lead health organizations or manage hospital systems. Choosing the right online degree can help you reach your career goals in medicine and healthcare more efficiently.

Best Scientists Citing James W. Mier

Trending Scientists

Recently Published Articles